Tenaya Therapeutics
TNYA· Manufacturing· Fiscal year ends in December
CEO pay in FY2025Stock -50.2% in FY2025
Faraz Ali, M.B.A. is the CEO of Tenaya Therapeutics and was paid $1.9M in FY2025 (Dec), down 43%.
Pay$100 in the stock at the end of FY21 → $4
Executives2
See all- 1Faraz Ali, M.B.A.Chief Executive OfficerFY2025
- 2Whittemore (Whit) Tingley, M.D., Ph.D.Chief Medical OfficerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allTenaya Therapeutics paid its 2 named executives $3.1M in total in FY2025 (Dec). CEO Faraz Ali, M.B.A. was paid $1.9M of that.
| Name | |||
|---|---|---|---|
| Faraz Ali, M.B.A.Chief Executive Officer | |||
| Whittemore (Whit) Tingley, M.D., Ph.D.Chief Medical Officer |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for Tenaya Therapeutics. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Board6
See all- Deepak Srivastava, M.D.Director · 9 yr on the boardIndependentScience and Technology—Paid as an executive
- Catherine Stehman-Breen, M.D.Director · 5 yr on the boardIndependentScience and Technology (Chair)—Paid as an executive
- Jeffrey T. Walsh, M.B.A.Director · 5 yr on the boardIndependent—Paid as an executive
- June Lee, M.D.Director · 4 yr on the boardIndependentScience and Technology—Paid as an executive
- Karah Parschauer, J.D.Director · 4 yr on the boardIndependent—Paid as an executive
- Amy Burroughs, M.B.A.Director · 3 yr on the boardIndependent—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 16, 2026 | FY2025 |
| Annual report | 10-K | Mar 11, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 17, 2025 | FY2024 |
| Annual report | 10-K | Mar 10, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 17, 2024 | FY2023 |
| Annual report | 10-K | Mar 18, 2024 | FY2023 |
